DelveInsight’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Autosomal Dominant Polycystic Kidney Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Autosomal Dominant Polycystic Kidney Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Overview
Autosomal dominant polycystic kidney disease, also called “adult PKD” is the most common inherited kidney disorder characterized by the growth of cysts in the kidneys, eventually leading to kidney failure. Autosomal Dominant Polycystic Kidney is a monogenetic disorder caused by mutations in either the PKD1 gene found on chromosome 16 or the PKD2 gene found on chromosome 4. Mutations in PKD1 are more common and account for about 85% of all Autosomal Dominant Polycystic Kidney Disease cases.
Autosomal Dominant Polycystic Kidney Disease is characterized by bilateral renal cysts, kidney pain, frequent urinary tract infection, hematuria, nephrolithiasis, hypertension, and progressive renal failure due to progressive enlargement of cysts and fibrosis. It is one of the leading causes of renal replacement and end-stage renal disease.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Key Facts
The market size of Autosomal Dominant Polycystic Kidney Disease in seven major markets was USD 1,077 million in 2021, which is further expected to increase significantly by 2032 in the forecast period 2022─2032.
The United States accounts for the largest market size for Autosomal Dominant Polycystic Kidney Disease compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Among the EU5 countries, the United Kingdom had the highest market size, with USD 79 million in 2021.
Upcoming therapies such as Bardoxolone methyl, Tesevatinib/KD019, and RGLS8429 have the potential to create a significant positive shift in the Autosomal Dominant Polycystic Kidney Disease market size.
Total diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in the 7MM were found to be approximately 367,000+ cases in the year 2021. The diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease are likely to change by 2032 in the forecast period 2022─2032.
In 2021, the total reported diagnosed prevalent cases of Autosomal Dominant Polycystic Kidney Disease in EU-5 countries were approximately 193,100+ cases which is expected to rise by 2032.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Autosomal Dominant Polycystic Kidney Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Autosomal Dominant Polycystic Kidney Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Autosomal Dominant Polycystic Kidney Disease (ADPKD) Epidemiology, Segmented by –
Total Diagnosed Prevalent Cases of ADPKD in the 7MM (2019–2032)
Age-specific Cases of ADPKD in the 7MM (2019–2032)
Mutation-specific Cases of ADPKD in the 7MM (2019–2032)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Autosomal Dominant Polycystic Kidney Disease market or expected to be launched during the study period. The analysis covers the Autosomal Dominant Polycystic Kidney Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Autosomal Dominant Polycystic Kidney Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Autosomal Dominant Polycystic Kidney Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/autosomal-dominant-polycystic-kidney-disease-market
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Analysis
Currently, there is no curative treatment for ADPKD, and most available treatments focus on managing the associated complication, delaying kidney function decline, and slowing cyst enlargement. Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB) are preferred by most specialists who treat hypertension in ADPKD patients. In individuals with ADPKD, these drugs may be more effective in preserving kidney function and preventing left ventricular hypertrophy than other therapies for hypertension.
There are several key companies developing therapies for Autosomal dominant polycystic kidney disease. Reata Pharmaceuticals is leading the therapeutics market with its Autosomal dominant polycystic kidney disease drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapeutics Market Include:
AceLink Therapeutics
Alebund Pharmaceuticals
Anakuria Therapeutics
Chinook Therapeutics
Galapagos NV
Healx
Janssen Pharmaceuticals
Kadmon Pharmaceuticals
Otsuka Pharmaceutical
Poxel
Reata Pharmaceuticals
Regulus Therapeutics
Sanofi
XORTX Therapeutics
And Many Others
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Therapies Covered in the Report Include:
GLPG2737: Galapagos NV
Bardoxolone methyl: Reata Pharmaceuticals
Tesevatinib/KD019: Sanofi
AT-20494: Janssen Pharmaceuticals
RGLS8429: Regulus Therapeutics
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Autosomal Dominant Polycystic Kidney Disease Competitive Intelligence Analysis
4. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance
5. Autosomal Dominant Polycystic Kidney Disease Disease Background and Overview
6. Autosomal Dominant Polycystic Kidney Disease Patient Journey
7. Autosomal Dominant Polycystic Kidney Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Autosomal Dominant Polycystic Kidney Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Autosomal Dominant Polycystic Kidney Disease Unmet Needs
10. Key Endpoints of Autosomal Dominant Polycystic Kidney Disease Treatment
11. Autosomal Dominant Polycystic Kidney Disease Marketed Products
12. Autosomal Dominant Polycystic Kidney Disease Emerging Drugs and Latest Therapeutic Advances
13. Autosomal Dominant Polycystic Kidney Disease Seven Major Market Analysis
14. Attribute Analysis
15. Autosomal Dominant Polycystic Kidney Disease Market Outlook (In US, EU5, and Japan)
16. Autosomal Dominant Polycystic Kidney Disease Access and Reimbursement Overview
17. KOL Views on the Autosomal Dominant Polycystic Kidney Disease Market
18. Autosomal Dominant Polycystic Kidney Disease Market Drivers
19. Autosomal Dominant Polycystic Kidney Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
